{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T07:07:28Z","timestamp":1777619248828,"version":"3.51.4"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,7,17]]},"DOI":"10.7759\/cureus.41990","type":"journal-article","created":{"date-parts":[[2023,7,17]],"date-time":"2023-07-17T08:13:51Z","timestamp":1689581631000},"source":"Crossref","is-referenced-by-count":1,"title":["Prevalence and Risk Factors of Anemia in Inflammatory Bowel Diseases: A Case-Control Study"],"prefix":"10.7759","author":[{"given":"Tahir","family":"Aslam","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asim","family":"Mehmood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s11938-018-0174-2","article-title":"Management of anemia in patients with inflammatory bowel disease (IBD)","volume":"16","author":"Patel D","year":"2018","unstructured":"Patel D, Trivedi C, Khan N. Management of anemia in patients with inflammatory bowel disease (IBD). Curr Treat Options Gastroenterol. 2018, 16:112-28. 10.1007\/s11938-018-0174-2","journal-title":"Curr Treat Options Gastroenterol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2015.10.012","article-title":"The burden of anaemia in patients with inflammatory bowel diseases","volume":"48","author":"Testa A","year":"2016","unstructured":"Testa A, Rispo A, Romano M, et al.. The burden of anaemia in patients with inflammatory bowel diseases. Dig Liver Dis. 2016, 48:267-70. 10.1016\/j.dld.2015.10.012","journal-title":"Dig Liver Dis"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2011.02.002","article-title":"Measurement of reticulocyte and red blood cell indices in the evaluation of anemia in inflammatory bowel disease","volume":"5","author":"Oustamanolakis P","year":"2011","unstructured":"Oustamanolakis P, Koutroubakis IE, Messaritakis I, Kefalogiannis G, Niniraki M, Kouroumalis EA. Measurement of reticulocyte and red blood cell indices in the evaluation of anemia in inflammatory bowel disease. J Crohns Colitis. 2011, 5:295-300. 10.1016\/j.crohns.2011.02.002","journal-title":"J Crohns Colitis"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1097\/01.MIB.0000442728.74340.fd","article-title":"Prevalence of anemia in inflammatory bowel diseases in European countries: a systematic review and individual patient data meta-analysis","volume":"20","author":"Filmann N","year":"2014","unstructured":"Filmann N, Rey J, Schneeweiss S, et al.. Prevalence of anemia in inflammatory bowel diseases in European countries: a systematic review and individual patient data meta-analysis. Inflamm Bowel Dis. 2014, 20:936-45. 10.1097\/01.MIB.0000442728.74340.fd","journal-title":"Inflamm Bowel Dis"},{"key":"ref5","article-title":"Iron deficiency anaemia","volume":"27","author":"Lopez A","year":"2016","unstructured":"Lopez A, Cacoub P, Macdougall IC, Peyrin-Biroulet L. Iron deficiency anaemia. Lancet. 2016, 27:907-16.","journal-title":"Lancet"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.4103\/jrms.JRMS_975_16","article-title":"Quality of life in inflammatory bowel disease patients: A cross-sectional study","volume":"22","author":"Habibi F","year":"2017","unstructured":"Habibi F, Habibi ME, Gharavinia A, Mahdavi SB, Akbarpour MJ, Baghaei A, Emami MH. Quality of life in inflammatory bowel disease patients: A cross-sectional study. J Res Med Sci. 2017, 22:104. 10.4103\/jrms.JRMS_975_16","journal-title":"J Res Med Sci"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2008.07.012","article-title":"Individualized treatment for iron deficiency anemia in adults","volume":"121","author":"Alleyne M","year":"2008","unstructured":"Alleyne M, Horne MK, Miller JL. Individualized treatment for iron deficiency anemia in adults. Am J Med. 2008, 121:943-8. 10.1016\/j.amjmed.2008.07.012","journal-title":"Am J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1744-9987.2010.00836.x","article-title":"2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease","volume":"14","author":"Tsubakihara Y","year":"2010","unstructured":"Tsubakihara Y, Nishi S, Akiba T, et al.. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease. Ther Apher Dial. 2010, 14:240-75. 10.1111\/j.1744-9987.2010.00836.x","journal-title":"Ther Apher Dial"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izab073","article-title":"Long-term effectiveness of oral ferric maltol vs intravenous ferric carboxymaltose for the treatment of iron-deficiency anemia in patients with inflammatory bowel disease: a randomized controlled noninferiority trial","volume":"28","author":"Howaldt S","year":"2022","unstructured":"Howaldt S, Dom\u00e8nech E, Martinez N, Schmidt C, Bokemeyer B. Long-term effectiveness of oral ferric maltol vs intravenous ferric carboxymaltose for the treatment of iron-deficiency anemia in patients with inflammatory bowel disease: a randomized controlled noninferiority trial. Inflamm Bowel Dis. 2022, 28:373-84. 10.1093\/ibd\/izab073","journal-title":"Inflamm Bowel Dis"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjad067","article-title":"Obefazimod: a first-in-class drug for the treatment of ulcerative colitis","volume":"2","author":"Vermeire S","year":"2023","unstructured":"Vermeire S, Solitano V, Peyrin-Biroulet L, et al.. Obefazimod: a first-in-class drug for the treatment of ulcerative colitis. J Crohns Colitis. 2023, 2:jjad067. 10.1093\/ecco-jcc\/jjad067","journal-title":"J Crohns Colitis"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S30015","article-title":"Pharmacokinetics of iron isomaltoside 1000 in patients with inflammatory bowel disease","volume":"6","author":"Nordfjeld K","year":"2012","unstructured":"Nordfjeld K, Andreasen H, Thomsen LL. Pharmacokinetics of iron isomaltoside 1000 in patients with inflammatory bowel disease. Drug Des Devel Ther. 2012, 6:43-51. 10.2147\/DDDT.S30015","journal-title":"Drug Des Devel Ther"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1080\/00365521.2016.1196496","article-title":"High-dose fast infusion of parenteral iron isomaltoside is efficacious in inflammatory bowel disease patients with iron-deficiency anaemia without profound changes in phosphate or fibroblast growth factor 23","volume":"51","author":"Dahlerup JF","year":"2016","unstructured":"Dahlerup JF, Jacobsen BA, van der Woude J, Bark L\u00c5, Thomsen LL, Lindgren S. High-dose fast infusion of parenteral iron isomaltoside is efficacious in inflammatory bowel disease patients with iron-deficiency anaemia without profound changes in phosphate or fibroblast growth factor 23. Scand J Gastroenterol. 2016, 51:1332-8. 10.1080\/00365521.2016.1196496","journal-title":"Scand J Gastroenterol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2013.335","article-title":"A randomized, open-label, non-inferiority study of intravenous iron isomaltoside 1,000 (Monofer) compared with oral iron for treatment of anemia in IBD (PROCEED)","volume":"108","author":"Reinisch W","year":"2013","unstructured":"Reinisch W, Staun M, Tandon RK, et al.. A randomized, open-label, non-inferiority study of intravenous iron isomaltoside 1,000 (Monofer) compared with oral iron for treatment of anemia in IBD (PROCEED). Am J Gastroenterol. 2013, 108:1877-88. 10.1038\/ajg.2013.335","journal-title":"Am J Gastroenterol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.15463","article-title":"Phase 1 study on the safety and efficacy of E6011, antifractalkine antibody, in patients with Crohn's disease","volume":"36","author":"Matsuoka K","year":"2021","unstructured":"Matsuoka K, Naganuma M, Hibi T, et al.. Phase 1 study on the safety and efficacy of E6011, antifractalkine antibody, in patients with Crohn's disease. J Gastroenterol Hepatol. 2021, 36:2180-6. 10.1111\/jgh.15463","journal-title":"J Gastroenterol Hepatol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2022-327897","article-title":"Hypophosphataemia following ferric derisomaltose and ferric carboxymaltose in patients with iron deficiency anaemia due to inflammatory bowel disease (PHOSPHARE-IBD): a randomised clinical trial","volume":"72","author":"Zoller H","year":"2023","unstructured":"Zoller H, Wolf M, Blumenstein I, et al.. Hypophosphataemia following ferric derisomaltose and ferric carboxymaltose in patients with iron deficiency anaemia due to inflammatory bowel disease (PHOSPHARE-IBD): a randomised clinical trial. Gut. 2023, 72:644-53. 10.1136\/gutjnl-2022-327897","journal-title":"Gut"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjw208","article-title":"Oral iron treatment response and predictors in anaemic adolescents and adults with IBD: a prospective controlled open-label trial","volume":"11","author":"Rampton DS","year":"2017","unstructured":"Rampton DS, Goodhand JR, Joshi NM, et al.. Oral iron treatment response and predictors in anaemic adolescents and adults with IBD: a prospective controlled open-label trial. J Crohns Colitis. 2017, 11:706-15. 10.1093\/ecco-jcc\/jjw208","journal-title":"J Crohns Colitis"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/168181-prevalence-and-risk-factors-of-anemia-in-inflammatory-bowel-diseases-a-case-control-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:05:25Z","timestamp":1707509125000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/168181-prevalence-and-risk-factors-of-anemia-in-inflammatory-bowel-diseases-a-case-control-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,17]]},"references-count":16,"URL":"https:\/\/doi.org\/10.7759\/cureus.41990","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7,17]]}}}